Nicotine Vaccine NicVax Show Favorable Clinical Trial Results
Filed in archive Drugs, Vaccines and Therapeutics by ruth on November 29, 2005

"The vaccine works by producing antibodiesthat specifically bind to nicotine and thereby prevent much of the nicotine from entering the brain. This process potentially reduces the pleasurable effects from smoking and reduces the addiction to nicotine."
The vaccines has few side effects,most of which were headaches, muscle pain and tenderness in the area of vaccine injection. There were no significant withdrawal symptoms reported, nor did the vaccine recepients exhibited compensatory smoking behavior, i.e. increased puffing on cigarettes to make up for the lower levels of nicotine reaching the brain.
Researchers say further studies are needed to establish the duration of its effectiveness and whether the vaccine can be used to prevent people who quit from relapsing and starting to smoke again.
It's definitely a promising method to help those who want to quit smoking. Want being the operative word.
For more info, read this article in theUMN News
Permalink: Nicotine Vaccine NicVax Show Favorable Clinical Trial Results
Tags:
nicotine vaccine biotech clinical favorable nicotine+vaccine trial+results clinical+trial
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/11604








